PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed ...

The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.

Pulse Biosciences (Nasdaq:PLSE) announced today that it appointed Liane Teplitsky as its new COO to further bolster its ...

Pulse Biosciences recently advanced its nPulse Cardiac Catheter Ablation System by enrolling the first patients in its pivotal NANOPULSE-AF IDE study for drug-resistant paroxysmal atrial fibrillation, ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Pulse Biosciences said Thursday it got the Food and Drug ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...

Pulse Biosciences is keeping the noise level up by announcing the enrollment of the first patients in the NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s ...